FrancophonIA/ELRC3.0 huggingface dataset:
English: Take the next dose, as normal, when it is due.
Croatian: OD LIJEKA, AKO JE POTREBNO
English: • Following recovery, resume ixazomib at its most recent dose.
Croatian: • Nakon oporavka nastavite terapiju iksazomibom pri posljednjoj dozi lijeka.
English: • The capsule shell contains: gelatin, titanium dioxide (E171), yellow iron oxide (E172)
Croatian: • Ovojnica kapsule sadrži: želatinu, titanijev dioksid (E171) i crveni željezov oksid (E172).
English: • Following recovery, resume lenalidomide at the next lower dose according to its prescribing information and resume ixazomib at its most recent dose.
Croatian: • Nakon oporavka, nastavite terapiju lenalidomidom u sljedećoj nižoj dozi u skladu s njegovim sažetkom opisa svojstava lijeka te nastavite s iksazomibom pri njegovoj posljednjoj dozi.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 3 mg of ixazomib (as 4.3 mg of ixazomib citrate)
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Jedna tvrda kapsula sadrži 3 mg iksazomiba (u obliku 4,3 mg iksazomibcitrata)
English: NAME OF THE MEDICINAL PRODUCT NINLARO 3 mg hard capsules ixazomib
Croatian: NAZIV LIJEKA NINLARO 3 mg tvrde kapsule iksazomib
English: MARKETING AUTHORISATION NUMBER(S) EU/1/16/1094/002
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/16/1094/002
English: NINLARO 4 mg hard capsules
Croatian: NINLARO 4 mg tvrde kapsule
English: Each capsule contains 3 mg of ixazomib (as 4.3 mg of ixazomib citrate).
Croatian: Jedna kapsula sadrži 3 mg iksazomiba (u obliku 4,3 mg iksazomibcitrata).
English: NINLARO 3 mg hard capsules
Croatian: NINLARO 3 mg tvrde kapsule
English: MARKETING AUTHORISATION NUMBER(S) EU/1/16/1094/003
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/16/1094/003
English: NINLARO 4 mg hard capsule: Light orange, size 3, marked “Takeda” on the cap and “4 mg” on the body with black ink.
Croatian: NINLARO 4 mg tvrde kapsule: svijetlonarančaste, veličine 3, s oznakom „Takeda“ na kapici i „4 mg“ na tijelu, otisnuto crnom tintom.
English: Three single blister wallet packs are packaged in one carton.
Croatian: Kartonska kutija sadrži tri pojedinačna ovitka s blisterom.
English: Light pink, size 4 gelatin hard capsule, marked “Takeda” on the cap and “2.3 mg” on the body with black ink.
Croatian: Svijetloružičaste, tvrde želatinske kapsule veličine 4, s oznakom „Takeda“ na kapici i „2,3 mg“ na tijelu, otisnuto crnom tintom.
English: Nausea
Croatian: Izlučivanje
English: NINLARO 3 mg hard capsule: Light grey, size 4, marked “Takeda” on the cap and “3 mg” on the body with black ink.
Croatian: NINLARO 3 mg tvrde kapsule: svijetlosive, veličine 4, s oznakom „Takeda“ na kapici i „3 mg“ na tijelu, otisnuto crnom tintom.
English: Please refer to the current lenalidomide SmPC.
Croatian: Pogledajte važeći sažetak opisa svojstava lijeka za lenalidomid.
English: Week 3
Croatian: 3. tje dan
English: Non-haematological toxicities
Croatian: Ne he matološke toksičnosti
English: Ixazomib did not prolong the QTc interval at clinically relevant exposures based on the results of a pharmacokinetic-pharmacodynamic analysis of data from 245 patients.
Croatian: Na temelju rezultata analize farmakokinetičkih i farmakodinamičkih podataka 245 bolesnika, klinički relevantna izloženost iksazomibu ne dovodi do produljenja QTc intervala.
English: Hepatic impairment
Croatian: Prekidi terapije
English: • Withhold ixazomib.
Croatian: • Odgodite primjenu iksazomiba.
English: Light orange, size 3 gelatin hard capsule, marked “Takeda” on the cap and “4 mg” on the body with black ink.
Croatian: Svijetlonarančaste, tvrde želatinske kapsule veličine 3, s oznakom „Takeda“ na kapici i „4 mg“ na tijelu, otisnuto crnom tintom.
English: The capsule shell contains: gelatin, titanium dioxide (E171) and red iron oxide (E172) The printing ink contains: shellac, propylene glycol, potassium hydroxide, and black iron oxide (E172).
Croatian: • Ovojnica kapsule sadrži: želatinu, titanijev dioksid (E171), žuti željezov oksid (E172) i crveni željezov oksid (E172).
English: Polska Takeda Pharma sp. z o.o
Croatian: Takeda Italia S.p.A.
English: What NINLARO looks like and contents of the pack NINLARO 2.3 mg hard capsule: Light pink, size 4, marked “Takeda” on the cap and “2.3 mg” on the body with black ink.
Croatian: NINLARO 2,3 mg tvrde kapsule: svijetloružičaste, veličine 4, s oznakom „Takeda“ na kapici i „2,3 mg“ na tijelu, otisnuto crnom tintom.
English: Light grey, size 4 gelatin hard capsule, marked “Takeda” on the cap and “3 mg” on the body with black ink.
Croatian: Svijetlosive, tvrde želatinske kapsule veličine 4, s oznakom „Takeda“ na kapici i „3 mg“ na tijelu, otisnuto crnom tintom.
English:  Daily  Daily  Daily Dexamethasone 
Croatian: 23. do dan iksazomib
English: Num of events:
Croatian: Proizvođač:
English: Magyarország Takeda Pharma Kft. Tel: +361 2707030
Croatian: Slove nská re publika Takeda Pharmaceuticals Slovakia s.r.o. Tel: +421 (2) 20 602 600
English: It is given according to official recommendations.
Croatian: Primjenjuje se na temelju službenih preporuka.
English: People who did not respond to the first dose can be given a second dose after at least four weeks.
Croatian: Osobe koje ne reagiraju na prvu dozu mogu primiti drugu dozu nakon barem četiri tjedna.
English: This will help to protect against diseases caused by these viruses.
Croatian: To pomaže u zaštiti od bolesti koje uzrokuju virusi.
English: It must also not be given to patients with certain blood or immune diseases.
Croatian: Također se ne smije davati bolesnicima s određenim bolestima krvi ili poremećajima imuniteta.
English: They should be re-vaccinated at between 12 and 15 months.
Croatian: Trebaju primiti dodatnu dozu cjepiva nakon 12 do 15 mjeseci.
English: The full EPAR for M-M-RVaxPro can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjeloviti EPAR za cjepivo M-M-RVaxPro nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use.
Croatian: Objašnjava kako je Agencija ocijenila cjepivo da bi preporučila njegovo odobrenje u EU-u te uvjete za njegovu primjenu.
English: It is given as one dose injected into a muscle or under the skin, preferably in the thighs of younger children and the shoulder in older children and adults.
Croatian: Daje se kao jednokratna injekcija u mišić ili pod kožu, po mogućnosti u bedro mlađe djece te u rame u starije djece i odraslih.
English: The European Commission granted a marketing authorisation valid throughout the European Union for M-M-RVaxPro on 5 May 2006.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za cjepivo M-M-RVaxPro na snazi u Europskoj uniji od 5. svibnja 2006.
English: Babies between nine and 12 months can be given the vaccine if they are considered to be at special risk, for example, if there is an outbreak in a day-care centre or the baby is travelling to an area where measles is common.
Croatian: Bebe u dobi od 9 do 12 mjeseci mogu primiti cjepivo ako se smatra da su izložene posebnom riziku, na primjer u slučaju izbijanja epidemije u jaslicama ili ako beba putuje u područje gdje su ospice česte.
English: In the future, the immune system will be able to produce antibodies more quickly when it is exposed to any of these viruses.
Croatian: U buduće će imunosni sustav moći brže proizvoditi protutijela ako je izloženo stvarnim virusima.
English: Injection site reactions were less common when the vaccine was injected into a muscle.
Croatian: Reakcije na mjestu injektiranja bile su rjeđe kad je cjepivo bilo injektirano u mišić.
English: When a person is given the vaccine, the immune system recognises the weakened viruses as ‘foreign' and makes antibodies against them.
Croatian: Kad osoba primi cjepivo, imunosni sustav prepoznaje oslabljeni virus kao „strano tijelo” i proizvodi protutijela na virus.
English: They may also be given an additional vaccination against measles.
Croatian: Također mogu primiti dodatno cjepivo protiv ospica.
English: Under some special circumstances, it can also be used in babies as young as nine months.
Croatian: U posebnom okolnostima također se može primijeniti u dojenčadi od 9 mjeseci i starijih.
English: This is a summary of the European public assessment report (EPAR) for M-M-RVaxPro.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) cjepiva M-M-RVaxPro.
English: For people with thrombocytopenia (low blood platelet counts) or any problems with blood clotting, the vaccine should only be injected under the skin to avoid bleeding.
Croatian: U osoba s trombocitopenijom (niska razina trombocita) i s problemima zgrušavanja krvi, cjepivo se smije injektirati samo pod kožu kako bi se izbjeglo krvarenje.
English: The CHMP decided that M-M-RVaxPro's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: CHMP je zaključio da koristi od cjepiva M-M-RVaxPro nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za njegovo stavljanje u promet.
English: However, the immune response for measles was lower in babies who started vaccination at nine months.
Croatian: Međutim, imunosni odgovor na ospice bio je niži u beba koje su prvi put cijepljene s devet mjeseci.
English: A fourth study in 1,620 babies was carried out with ProQuad (a vaccine that contains similar weakened viruses to those of M-M-RVaxPro).
Croatian: Četvrto ispitivanje na 1620 beba provedeno je s cjepivom ProQuad (cjepivom koje sadrži slične oslabljene viruse kao i M-M-RVaxPro).
English: The company that makes M-M-RVaxPro will continue to monitor the side effects to see if using recombinant albumin in the manufacturing process of M-M-RVaxPro leads to side effects such as allergic reactions.
Croatian: Tvrtka koja proizvodi M-M-RVaxPro nastavit će pratiti nuspojave kako bi se utvrdilo da li korištenje rekombinantnog albumina u proizvodnom postupku cjepiva M-M-RVaxPro uzrokuje nuspojave poput alergijskih reakcija.
English: What measures are being taken to ensure the safe and effective use of M-M-RVaxPro?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena cjepiva M-M-RVaxPro?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of M-M-RVaxPro have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene cjepiva M-M-RVaxPro nalaze se u sažetku opisa svojstava i u uputi o cjepivu.
English: This study showed that, after the second dose, the production of antibodies against mumps and rubella in babies who started vaccination as young as nine months was similar to those of babies who started vaccination at 12 months.
Croatian: U tom se ispitivanju pokazalo da je nakon druge doze razina protutijela protiv zaušnjaka i rubeole u beba cijepljenih u dobi od devet mjeseci bila slična onoj u beba koje su prvu dozu cjepiva primile s 12 mjeseci.
English: A second study in 1,997 children looking specifically at mumps showed that M-M-RVaxPro led to sufficient amounts of antibodies against mumps, while a third study in 776 children showed that immune responses triggered by M-M-RVaxPro were the same regardless of whether it was injected into a muscle or under the skin.
Croatian: U drugom ispitivanju na 1997 djece koje se posebno odnosilo na zaušnjake, cjepivo M-M-RVaxPro potaknulo je razvoj dovoljne količine protutijela protiv zaušnjaka, dok se u trećem ispitivanju na 776 djece pokazalo da je imunosni odgovor koji je potaknulo cjepivo M-MRVaxPro bio isti, bez obzira na to je li injekcija dana u mišić ili pod kožu.
English: What is M-M-RVaxPro and what is it used for?
Croatian: Što je M-M-RVaxPro i za što se koristi?
English: In a study of 1,279 children, M-M-RVaxPro triggered the same level of immune response as a comparator vaccine, with more than 98% of vaccinated patients having sufficient levels of antibodies against the three viruses.
Croatian: U ispitivanju provedenom na 1279 djece, cjepivo M-M-RVaxPro potaknulo je istu razinu imunosnog odgovora kao i usporedno cjepivo, pri čemu je više od 98 % cijepljenih osoba razvilo dovoljne količine protutijela protiv ta tri virusa.
English: The most common side effects with M-M-RVaxPro (seen in more than 1 patient in 10) are fever (38.5°C or higher), and injection site redness, pain and swelling.
Croatian: Najčešće nuspojave cjepiva M-M-RVaxPro (zabilježene u više od 1 na 10 osoba) su vrućica (38,5 °C ili viša) te crvenilo, bol i oticanje na mjestu injektiranja.
English: It is not intended to provide practical advice on how to use M-M-RVaxPro.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni cjepiva M-M-RVaxPro.
English: M-M-RVaxPro should not be used in people who may be hypersensitive (allergic) to any measles, mumps or rubella vaccine, or to any of the ingredients, including neomycin (an antibiotic).
Croatian: M-M-RVaxPro ne smiju primiti osobe koje su preosjetljive (alergične) na bilo koje cjepivo za ospice, zaušnjake ili rubeolu, kao i one alergične na druge sastojke poput neomicina (antibiotik).
English: For more information about treatment with M-M-Rvaxpro, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju cjepivom M-M-Rvaxpro, pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: M-M-RVaxPro is a vaccine.
Croatian: M-M-RVaxPro je cjepivo.
English: M-M-RVaxPro is available as a powder and solvent that are made up into a suspension for injection.
Croatian: Cjepivo M-M-RVaxPro dostupno je kao prašak i otapalo od kojih se priprema otopina za injekciju.
English: M-M-RVaxPro is a vaccine used to protect adults and children aged 12 months or older against measles, mumps, and rubella (German measles).
Croatian: M-M-RVaxPro je cjepivo za zaštitu odraslih i djece u dobi od 12 mjeseci i starijih od ospica, zaušnjaka i rubeole (crljenca).
English: Other information about M-M-RVaxPro
Croatian: Ostale informacije o cjepivu M-M-RVaxPro
English: M-M-RVaxPro must not be given during pregnancy, any illness with fever (over 38.5°C) or active untreated tuberculosis (TB).
Croatian: M-M-RVaxPro ne smije se davati trudnicama, za vrijeme vrućice (od 38,5 °C ili više) uzrokovane bilo kojom bolešću kao ni kod aktivne, neliječene tuberkuloze.
English: What are the risks associated with M-M-RVaxPro?
Croatian: Koji su rizici povezani s cjepivom M-M-RVaxPro?
English: For practical information about using M-M-RVaxPro, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni cjepiva M-M-RVaxPro bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: M-M-RVaxPro contains small amounts of weakened forms of the viruses that cause measles, mumps, and rubella.
Croatian: Cjepivo M-M-RVaxPro sadrži male količine oslabljenih oblika virusa koji uzrokuju ospice, zaušnjake i rubeolu.
English: M-M-RVaxPro contains live attenuated (weakened) measles, mumps and rubella viruses.
Croatian: Cjepivo M-M-RVaxPro sadrži žive atenuirane (oslabljene) viruse ospica, zaušnjaka i rubeole.
English: Why is M-M-RVaxPro approved?
Croatian: Zašto je cjepivo M-M-RVaxPro odobreno?
English: What benefits of M-M-RVaxPro have been shown in studies?
Croatian: Koje su koristi od cjepiva M-M-RVaxPro dokazane u ispitivanjima?
English: M-M-RVaxPro has been shown in studies to be effective at triggering the production of a sufficient amount of antibodies to protect against measles, mumps, and rubella.
Croatian: Ispitivanja su pokazala da je cjepivo M-M-RVaxPro djelotvorno u proizvodnji dovoljne količine protutijela u organizmu za zaštitu od ospica, zaušnjaka i rubeole.
English: How does M-M-RVaxPro work?
Croatian: Kako djeluje M-M-RVaxPro?
English: How is M-M-RVaxPro used?
Croatian: Kako se M-M-RVaxPro koristi?
English: For the full list of all side effects reported with M-M-RVaxPro, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni cjepiva M-MRVaxPro potražite u uputi o lijeku.
English: You will probably need to lie down until you feel better.
Croatian: Vjerojatno ćete morati leći dok se ne budete osjećali bolje.
English: Powder: 3 years.
Croatian: Prašak: 3 godine.
English: No more injections will be given to you.
Croatian: Nećete primiti više niti jednu injekciju.
English: Volume of injection (ml)
Croatian: Volumen injekcije (ml)
English: Solution (after reconstitution): 1 hour.
Croatian: Otopina (nakon rekonstitucije): 1 sat.
English: There is no experience in children.
Croatian: Nema iskustva o primjeni u djece.
English: Especially tell your doctor if you are taking medicines for Parkinson's disease.
Croatian: Posebno obavijestite svog liječnika ako uzimate lijekove protiv Parkinsonove bolesti.
English: Up to 20 mg in 24 hours may be given.
Croatian: Može se primijeniti do 20 mg unutar 24 sata.
English: This leaflet was last revised in {month XXXX}
Croatian: Ova uputa je zadnji puta revidirana u {mjesec GGGG}
English: Date of latest renewal: 12 September 2006
Croatian: Datum posljednje obnove odobrenja: 12. rujna 2006.
English: Do not freeze after reconstitution.
Croatian: Ne zamrzavati nakon pripreme za primjenu.
English: Rotate the vial until the contents have completely dissolved, giving a yellow coloured solution.
Croatian: Okrećite bočicu dok se sadržaj u potpunosti ne otopi, stvarajući otopinu žute boje.
English: This will usually pass on its own but if it does not, tell your doctor or a nurse as soon as possible.
Croatian: Ovo obično prolazi samo po sebi, ali ako ne prođe, obavijestite liječnika ili medicinsku sestru što je prije moguće.
English: The dose is usually 10 mg for the first injection, but it may be less than this.
Croatian: Uobičajena doza iznosi 10 mg za prvu injekciju, ali može biti i manja.
English: ZYPREXA with alcohol
Croatian: ZYPREXA s alkoholom
English: The recommended starting dose in elderly patients (> 60 years) is 2.5 - 5 mg.
Croatian: Preporučena početna doza u starijih bolesnika (> 60 godina) iznosi 2,5 do 5 mg.
English: You should take your ZYPREXA tablets once a day following the advice of your doctor.
Croatian: ZYPREXA tablete morate uzimati jednom dnevno pridržavajući se savjeta svog liječnika.
English: ZYPREXA powder for solution for injection should be reconstituted in accordance with the recommendation in section 6.6.
Croatian: ZYPREXA prašak za otopinu za injekciju treba rekonstituirati u skladu s preporukama u dijelu 6.6.
English: ZYPREXA powder for solution for injection is intended for short term use only, for up to a maximum of three consecutive days.
Croatian: ZYPREXA prašak za otopinu za injekciju namijenjen je samo za kratkotrajnu primjenu, tijekom najviše tri uzastopna dana.
English: The correct amount of solution will be injected into your muscle.
Croatian: Točna doza otopine bit će Vam ubrizgana u mišić.
English: The maximum daily dose of olanzapine (including all formulations of olanzapine) is 20 mg.
Croatian: Maksimalna dnevna doza olanzapina (uključujući sve formulacije olanzapina) je 20 mg.
English: Fertility Effects on fertility are unknown (see section 5.3 for preclinical information).
Croatian: Nisu poznati učinci na plodnost (vidjeti dio 5.3 za pretkliničke podatke).
English: See examples below.
Croatian: Vidjeti primjere u nastavku.
English: Other medicines and ZYPREXA
Croatian: Drugi lijekovi i ZYPREXA
English: Tell your doctor or nurse of your concern.
Croatian: Recite liječniku ili medicinskoj sestri ako ste zabrinuti.
English: Unstable medical conditions
Croatian: Nestabilna medicinska stanja
English: ZYPREXA is available in packs containing 28, 35, 56, 70 or 98 tablets.
Croatian: ZYPREXA je dostupna u pakiranjima koja sadrže 28, 35, 56, 70 ili 98 tableta.
English: However, the combination added to the somnolence observed with either medicines alone.
Croatian: Međutim, kombinacija je pojačala somnolenciju opaženu kod samostalne primjene obaju lijekova.
English: A second injection, 5-10 mg, may be administered 2 hours after the first injection on the basis of individual clinical status.
Croatian: Druga injekcija, 5 do 10 mg, može se primijeniti 2 sata nakon prve injekcije na temelju kliničkog statusa pojedinog bolesnika.
English: In patients with Parkinson's disease ZYPREXA may worsen the symptoms.
Croatian: U bolesnika koji boluju od Parkinsonove bolesti, ZYPREXA može pogoršati simptome.
English: The following table provides injection volumes for delivering various doses of olanzapine:
Croatian: Sljedeća tablica prikazuje volumene injekcija za primjenu različitih doza olanzapina:
English: The Cmax occurs earlier after intramuscular compared to oral use (15 to 45 minutes versus 5 to 8 hours).
Croatian: Cmax se doseže ranije nakon intramuskularne primjene nego nakon peroralne primjene (15-45 minuta naspram 5-8 sati).
English: The dose for patients aged over 65 years is 2.5 mg or 5 mg.
Croatian: Doza za bolesnike starije od 65 godina iznosi 2,5 mg ili 5 mg.
English: Adolescents (ages 13 to 17 years): The pharmacokinetics of olanzapine are similar between adolescents and adults.
Croatian: Pedijatrijska populacija Adolescenti (u dobi od 13 do 17 godina): farmakokinetika olanzapina je slična između adolescenata i odraslih.
English: Your doctor will decide when you need a dose of ZYPREXA Injection.
Croatian: Vaš će liječnik odrediti kada trebate primiti injekciju lijeka ZYPREXA.
English: FURTHER INFORMATION
Croatian: DRUGE INFORMACIJE
English: Tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Croatian: Obavijestite svog liječnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući i one koje ste nabavili bez recepta.
English: ZYPREXA belongs to a group of medicines called antipsychotics and is used to treat the following conditions:
Croatian: ZYPREXA pripada skupini lijekova koji se zovu antipsihotici i koristi se za liječenje sljedećih stanja:
English: Discard the syringe and any unused solution in accordance with appropriate clinical procedures.
Croatian: Zbrinite štrcaljku i svu neiskorištenu otopinu sukladno odgovarajućim kliničkim postupcima.
English: The exact amount is shown on your ZYPREXA tablet pack.
Croatian: Točna količina navedena je na pakiranju ZYPREXA tableta.
English: OTHER INGREDIENTS
Croatian: DRUGI SASTOJCI
English: • carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your ZYPREXA dose.
Croatian: • karbamazepin (antiepileptik i stabilizator raspoloženja), fluvoksamin (antidepresiv) ili ciprofloksacin (antibiotik) - možda će biti potrebno promijeniti dozu lijeka ZYPREXA.
English: Because olanzapine may cause somnolence and dizziness, patients should be cautioned about operating machinery, including motor vehicles.
Croatian: obzirom da olanzapin može uzrokovati somnolenciju i omaglicu, bolesnici moraju biti oprezni kod upravljanja strojevima, uključujući motorna vozila.
English: Unlike some other antipsychotic agents, olanzapine increases responding in an “anxiolytic” test.
Croatian: Za razliku od nekih drugih antipsihotika, olanzapin povećava odgovor u “anksiolitičkom”
English: • Tell the doctor or nurse if you feel dizzy or faint after the injection.
Croatian: • Obavijestite liječnika ili medicinsku sestru ako nakon injekcije osjećate omaglicu ili nesvjesticu.
English: • Mania, a condition with symptoms of excitement or euphoria.
Croatian: • manije, stanja sa simptomima uzbuđenja ili euforije.
English: The mean increase in olanzapine Cmax following fluvoxamine was 54 % in female nonsmokers and 77 % in male smokers.
Croatian: Srednja vrijednost porasta Cmax olanzapina nakon primjene fluvoksamina iznosio je 54% u žena nepušača i 77% u muškaraca pušača.